In experimental diabetes SGLT2 inhibitors controlled hyperglycemia and limited albuminuria and renal damage, including glomerular mesangial matrix accumulation and interstitial fibrosis, through combined effects on glomerular hemodynamics and the inhibition of inflammation and oxidative stress (Gembardt et al., 2014; Terami et al., 2014; Vallon et al., 2014; Wang et al., 2017). Here, SLC5A2 is linked to Hyperglycemia.